First Tracks Biotherapeutics, Inc. (TRAX)
Market Closed
14 Sep, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary 
XDUS $
37. 57
+1.13
+3.101%
$
1.27B Market Cap
- P/E Ratio
- Div Yield
397,122 Volume
- Eps
$ 36.44
Previous Close Investors:
Want to track TRAX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
TRAX closed today higher at $37.57, an increase of 3.101% from yesterday's close, completing a monthly decrease of -13.6123% or -$5.92. Over the past 12 months, TRAX stock gained 87.85%.
TRAX is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
TRAX Chart
First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long
First Tracks Biotherapeutics, spun off from AnaptysBio, launches with $180M cash and a diverse, early-stage pipeline. I rate TRAX as a Hold due to post-spin instability, near-term dilution risk, and a multi-year path to revenue. ANB033 targets celiac disease, with no current FDA-approved therapies; pivotal trial data are expected in Q4 2026–2027, with commercialization likely a decade away.
Seekingalpha | 4 months ago
First Tracks Biotherapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 408,330 | $7.26M | $17.98M | $10.72M | 147.69% |
 Joseph Castro Nuveen LLC | 49,608 | $882,030.24 | $1.87M | $984,108.62 | 111.57% |
 Li Peng China Universal Asset Management Co. Ltd. | 5,553 | $98,732.34 | $244,554.13 | $145,821.79 | 147.69% |
 Ana-Maria Ignat Covestor Ltd | 29 | $515.62 | $1,314.57 | $798.95 | 154.95% |
 Kevin Roan Stempoint Capita LLP | 622,723 | $11.07M | $23.42M | $12.35M | 111.53% |
First Tracks Biotherapeutics, Inc. (TRAX) FAQ
What is the stock price today?
The current price is $37.57.
On which exchange is it traded?
First Tracks Biotherapeutics, Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is TRAX.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 1.27B.
Has First Tracks Biotherapeutics, Inc. ever had a stock split?
No, there has never been a stock split.
First Tracks Biotherapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Daniel R. Faga CEO | NASDAQ (NGS) Exchange | 337185102 CUSIP |
| US Country | 104 Employees | - Last Dividend | - Last Split | - IPO Date |
First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
Contact Information
Address: 10770 Wateridge Circle
Phone: 858 362 6295
Website: https://www.firsttracksbio.com
